在帕金森病中使用多巴胺激动剂治疗:西班牙专家就其在不同临床情况下的使用达成共识
D Santos García1, J Pagonabarraga Mora2, F Escamilla Sevilla3
1Servicio de Neurología, CHUAC (Complejo Hospitalario Universitario de A Coruña), As Xubias 84, 15006 A Coruña, Spain.
Neurologia
|July 7, 2023
概括
这项研究为使用多巴胺激动剂 (DA) 治疗帕金森病 (PD) 提供了专家共识. 建议涵盖早期PD,运动并发症,副作用以及指导临床医生和患者的具体情景.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 管理涉及各种运动和非运动症状的治疗方法.
- 多巴胺激动剂 (DA) 治疗是PD的关键治疗方式.
研究的目的:
- 在帕金森病 (PD) 患者的不同临床情况中,就多巴胺激动剂 (DA) 治疗的最佳使用情况达成专家共识.
- 为PD的DA治疗制定基于证据的建议.
主要方法:
- 一种名义上的小组技术,涉及12名PD专家神经科医生.
- 一项基于互联网的调查,48名西班牙神经科医生投票对初步陈述.
- 达成共识,如果陈述达到了利克特尺度上≥3.5分.
主要成果:
- 达成共识的小组产生了76个现实世界的建议.
- 建议涵盖了早期PD的DA治疗,运动并发症,副作用和特定的临床情景.
- 在15个声明上没有达成共识.
结论:
- 达成共识的研究结果为在PD的不同阶段和临床背景下适当应用DA治疗提供了指导.
- 这项研究作为一个探索性步骤,以帮助临床医生和患者做出关于DA使用的明智决策.
相关概念视频
Parkinson's Disease: Treatment
302
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
302
Parkinson's Disease: Overview
606
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
606
Drug Therapy
74
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
74
Psychosis: Goals of Pharmacotherapy
170
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
170
Direct-Acting Cholinergic Agonists: Therapeutic Uses
796
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
796
Alzheimer's Disease: Treatment
220
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
220


